Subgroups according to BASDAI/ASDAS category (baseline)

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents

Additional Data in Active PsA

Refining the Focus: A New Look at Spondylitis

Disease Control Data, Ankylosing Spondylitis

JCM, Free Full-Text

Comparison of (A) ASDAS vs SASDAS in their capacity to each

POS0235 COMPARISON OF AXIAL AND PERIPHERAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN UPADACITINIB CLINICAL TRIALS

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study - Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D'Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano

Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis, Health and Quality of Life Outcomes

Full article: POSTER PRESENTATIONS

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab